

online from January 2009



**in vivo**

International Journal of Experimental and Clinical  
Pathophysiology and Drug Research

Published by the International Institute of Anticancer Research

ISSN (print): 0258-851X; ISSN (online): 1791-7549

### General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

### Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: [www.iiar-anticancer.org](http://www.iiar-anticancer.org)

### Selection of Recent Articles

Small Molecule GS-Nitroxide Ameliorates Ionizing Irradiation-Induced Delay in Bone Wound Healing in a Novel Murine Model. A. GOKHALE, J.-C. RWIGEMA, M. EPPERLY, J. GLOWACKI, H. WANG, P. WIPF., J. GOFF, T. DIXON, K. PATRENE, J.S. GREENBERGER (*Pittsburgh, PA; Boston, MA, USA*)

A Non-traumatic *Staphylococcus aureus* Osteomyelitis Model in Pigs. H.E. JENSEN, O.L.NIELSEN, J.S. AGERHOLM, T. IBURG, L.K. JOHANSEN, E. JOHANNESSEN, M. MØLLER, L. JAHN, L. MUNK, B. AALBZ K, P.S. LEIFSSON (*Frederiksberg C, Denmark*)

Effects of Voluntarily Ingested Buprenorphine on Plasma Corticosterone Levels, Body Weight, Water Intake, and Behaviour in Permanently Catheterised Rats. R. GOLDKUHL, J. HAU, K.S.P. ABELSON (*Uppsala, Sweden; Copenhagen, Denmark*)

Pharmacologic Ascorbic Acid Suppresses Syngeneic Tumor Growth and Metastases in Hormone-Refractory Prostate Cancer. H.B. POLLARD, M.A. LEVINE, O. EIDELMAN, M. POLLARD (*Bethesda, MD; Notre Dame, IN, USA*)

Uterus Cryopreservation in the Sheep: One Step Closer to Uterus Transplantation. R. DITTRICH, T. MALTARIS, A. MUELLER, O. STRAHL, I. HOFFMANN, M.W. BECKMANN, P.G. OPPELT (*Erlangen, Germany*)

Modulation of Aged Murine T Lymphocytes *In Vivo* by DPV576-C, a Nanodiamond- and Nanoplatinum-coated Material. M. GHONEUM, A. GHONEUM, L. TOLENTINO, J. GIMZEWSKI (*Los Angeles, CA, USA*)

Twice Weekly Intravenous Treatment of Pancreatic Cancer with Atrial Natriuretic Peptide and Vessel Dilator. A. LENZ, Y. SUN, E.J. EICHELBAUM, W.P. SKELTON, IV, G. PI, D.L. VESELY (*Tampa, FL, USA*)

Successful Anatomic Repair of Fetoscopic Access Sites in the Mid-gestational Rabbit Model using Amnion Cells Engineering. N.A. PAPADOPULOS, D.I. KYRIAKIDIS, U. SCHILLINGER, A. TOTIS, J. HENKE, L. KOVACS, R.E. HORCH, K.T.M. SCHNEIDER, H.-G. MACHENS, E. BIEMER (*Munich; Erlangen, Germany*)

Effects of Fetal Exposure to 4-*n*-octylphenol on Mammary Tumorigenesis in Rats. H. KAWAGUCHI, N. MIYOSHI, Y. MIYAMOTO, M. SOUDA, Y. UMEKITA, N. YASUDA, H. YOSHIDA (*Kagoshima, Japan*)

Comparative Study of Difference Between Long and Short Pulse on Treating Melanoma *In Vivo*. X. CHEN, R.J. SWANSON, K.H. SCHOENBACH, S. ZHENG (*Zhejiang, China; Norfolk, VA, USA*)

Tetrandrine Pre-Treatment has Protective Effects Against Isoproterenol-induced Myocardial Infarction in Rabbits. A. PINELLI, S. TRIVULZIO, S. BRENNNA, G. ROSSONI (*Milan, Italy*)

Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUNDAL, K.-M. MYHR, H.I. YLAND (*Bergen, Norway*)

Development of fMRI Tests for Children with Central Auditory Processing Disorders. S. BARTEL-FRIEDRICH, Y. BROECKER, M. KNOERGEN, S. KOESLING (*Halle/Saale, Germany*)

Chronic Hind Limb Ischemia Reduces Myocardial Ischemia-reperfusion Injury in the Rabbit Heart by Promoting Coronary Angiogenesis/Arteriogenesis. V.C. VARNAVAS, K.I. PARASKEVAS, E.K. ILIODROMITIS, A. ZOGA, I. GLAVA, L. KAKLAMANIS, J. SPARTINOS, T. LYRAS, D.T. KREMASTINOS, D.P. MIKHAILIDIS, Z.S. KYRIAKIDES (*Athens, Greece; London, UK*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

## Instructions to Authors

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

*Tables.* Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

*References.* Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Submission of Manuscripts.* Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios

International Institute of Anticancer Research (IIAR)  
Editorial Office of ANTICANCER RESEARCH,  
IN VIVO, CANCER GENOMICS and PROTEOMICS.  
1st km Kapandritiou-Kalamou Road  
P.O. Box 22, GR-19014 Kapandriti, Attiki  
GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

*Reprints.* Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

# CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009) - VOL.7 (2010)

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, <sup>a</sup>DLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

## Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

## A Selection of Recent Papers

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGENWERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (*Düsseldorf, Germany*)

Cancer-related Issues of CD147. U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN, H. STOCKINGER (*Penzburg, Germany; Vienna, Austria*)

Spontaneous *In Vitro* Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (*München; Düsseldorf; Rostock, Germany*)

Inhibition of c-Jun N-terminal Kinase (JNK) by SP600125 : A cDNA Microarray Analysis. P. CHAMPELOVIER, M. EL ATIFI-BOREL, J.P. ISSARTEL, J. BOUTONNAT, F. BERGER, D. SEIGNEURIN (*Grenoble, France*)

Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in Human Breast Cancer, Expression Pattern and Clinical/Prognostic Relevance. S. CHENG, A. DOUGLAS-JONES, X. YANG, R.E. MANSEL, W.G. JIANG (*Cardiff, UK; Beijing, China*)

Spontaneous *In Vitro* Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (*München; Düsseldorf; Rostock, Germany*)

Metalloproteome of the Prostate: Carcinoma Cell Line DU-145 in Comparison to Healthy Rat Tissue. J. BARTEL, E. CHARKIEWICZ, T. BARTZ, J. BARTEL, D. SCHMIDT, I. GRBAVAC, A. KYRIAKOPOULOS (*Berlin, Germany*)

Discovery of Serum Protein Biomarkers for Prostate Cancer Progression by Proteomic Analysis. J. AL-RUWAILI, S.E.T. LARKIN, B.A. ZEIDAN, M.G. TAYLOR, C.N. ADRA, P.A. TOWNSEND, C.L. AUKIM-HASTIE (*Portsmouth; Southampton, UK; Riyadh, Saudi Arabia; Boston, MA, USA*)

Identification of Serpin ( $\alpha$ -1-antitrypsin) as Serum Growth Inhibitory Factor in Murine Ehrlich Carcinoma by Proteomics. F.V. DONENKO, R.K. ZIGANSHIN, N.Y. ANISIMOVA, K.E. VOYUSHIN, S.M. SITDIKOVA, B.S. AMANDZHOLOV, M.V. KISELEVSKII, T. EFFERTH (*Moscow, Russia; Mainz, Germany*)

DNA-Based Assay for EPHB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (*Pomona, CA, USA*)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDER, E. BLOMQUIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (*Uppsala; Örebro; Gävle; Karlstad, Sweden; Mumbai, India*)

Efficacy of the Progesterone Receptor Antagonist Mifepristone for Palliative Therapy of Patients with a Variety of Advanced Cancer Types. J.H. CHECK, E. DIX, R. COHEN, D. CHECK, C. WILSON ( <i>Camden, NJ, USA</i> ) .....	623
Effect of YB-1 on the Regulation of Micro RNA Expression in Drug-sensitive and Drug-resistant Gastric Carcinoma Cells. E. BELIAN, R. KURUCZ, D. TREUE, H. LAGE ( <i>Berlin, Germany</i> ) .....	629
Assessment of the Prognostic Indices IPI and FLIPI in Patients with Mucosa-associated Lymphoid Tissue Lymphoma. M. TROCH, S. WÖHRER, M. RADERER ( <i>Vienna, Austria</i> ) .....	635
Type 2 and Clear Cell Papillary Renal Cell Carcinoma, and Tubulocystic Carcinoma: A Unifying Concept. C. BRENNAN, J.R. SRIGLEY, C. WHELAN, J. COOPER, B. DELAHUNT ( <i>Woolloongabba, QLD; Woodville, SA, Australia; Hamilton, ON, Canada; Wellington, New Zealand</i> ) .....	641
Prognostic and Predictive Value of Thymidylate Synthase Expression in Primary Colorectal Cancer. M. KARLBERG, K. ÖHRLING, D. EDLER, M. HALLSTRÖM, H. ULLÉN, P. RAGNHAMMAR ( <i>Stockholm, Sweden</i> ) .....	645
Predictors of Survival in Stage IV Metastatic Colorectal Cancer. M. ZACHARAKIS, I.D. XYNOS, A. LAZARIS, T. SMARO, C. KOSMAS, A. DOKOU, E. FELEKOURAS, E. ANTONIOU, A. POLYZOS, J. SARANTONIS, J. SYRIOS, G. ZOGRAFOS, A. PAPALAMBROS, N. TSAVARIS ( <i>Athens; Piraeus, Greece</i> ) .....	653
Specificity of Fusion Genes in Adipocytic Tumors. T. KUBO, Y. MATSUI, N. NAKA, N. ARAKI, A. MYOUI, K. ENDO, N. YASUI, O. OHTANI, K. SUZUKI, T. KIMURA, H. YOSHIKAWA, T. UEDA ( <i>Tokushima; Toyama; Osaka, Japan</i> ) .....	661
Differential Display Code 3 (DD3/PCA3) in Prostate Cancer Diagnosis. J. KLECKA, L. HOLUBEC, M. PESTA, O. TOPOLCAN, M. HORA, V. ERET, J. FINEK, M. CHOTTOVA-DVORAKOVA, M. BABJUK, K. NOVAK, J. STOLZ ( <i>Plzen; Prague, Czech Republic</i> ) .....	665
EGFR Status and Prognosis of Patients with Locally Advanced Head and Neck Cancer Treated with Chemoradiotherapy. G. NUMICO, E.G. RUSSI, I. COLANTONIO, R.A. LANTERMO, N. SILVESTRIS, R. VITIELLO, A. COMINO, M. ABRATE, C. ZAVATTERO, A. MELANO, M. MERLANO ( <i>Aosta; Cuneo; Bari; Savigliano, Italy</i> ) .....	671
A Case of Curative-intent Hepatectomy for Colon Cancer Metastatic to the Scapula and Liver. G. VAIDYANATHAN, M.G. FAKIH ( <i>Buffalo, NY, USA</i> ) .....	677
The Relationship between Obesity and Cancer Mortality in Type 2 Diabetes: A Ten-year Follow-up Study (ZODIAC-21). G.W. LANDMAN, K.J.J. VAN HATEREN, N. KLEEFSTRA, H.J.G. BILO ( <i>Zwolle; Groningen, The Netherlands</i> ) .....	681
The Body Image Drawing Analysis in Women with Breast Disease and Breast Cancer: Anxiety, Colour and Depression Categories. M. ESKELINEN, P. OLLONEN ( <i>Kuopio, Finland</i> ) .....	683
Regulation of mRNA Expression in Drug-sensitive and Drug-resistant Gastric Carcinoma Cells Is Independent of YB-1 Expression. R. KURUCZ, E. BELIAN, D. TREUE, H. LAGE ( <i>Berlin, Germany</i> ) .....	693
Modifications of Nuclear Envelope in Tumour Cells of Human Gastric Carcinomas: An Ultrastructural Study. R.A. CARUSO, L. RIGOLI, F. FEDELE, G. PIZZI, E. QUATTROCCHI, G. FINOCCHIARO, A. LABATE, D. PAPARO, R. LUCIANÒ, A. PARISI, A. VENUTI ( <i>Messina, Italy</i> ) .....	699
* Reviews (pages 279, 455, 601) .....	

Epigenetic Modifiers as Anticancer Drugs: Effectiveness of Valproic Acid in Neural Crest-derived Tumor Cells. A. PAPI, A.M. FERRERI, P. ROCCHI, F. GUERRA, M. ORLANDI ( <i>Bologna, Italy</i> ) .....	535
<i>Clinical Studies</i>	
Phase II Study of Liposomal Cisplatin (SPI-77) in Platinum-sensitive Recurrences of Ovarian Cancer. N. SEETHARAMU, E. KIM, H. HOCHSTER, F. MARTIN, F. MUGGIA ( <i>New York, NY; Mountain View, CA, USA</i> ) .....	541
Phase II Clinical Trial of Imatinib Mesylate in Therapy of KIT and/or PDGFR $\alpha$ -expressing Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors. J. CHAO, G.T. BUDD, P. CHU, P. FRANKEL, D. GARCIA, M. JUNQUEIRA, S. LOERA, G. SOMLO, J. SATO, W.A. CHOW ( <i>Duarte, CA; Cleveland, OH, USA</i> ) .....	547
Pelvic Floor Rehabilitation for Continence Recovery after Radical Prostatectomy: Role of a Personal Training Re-Educational Program. D. MARCHIORI, A. BERTACCINI, F. MANFERRARI, C. FERRI, G. MARTORANA ( <i>Bologna, Italy</i> ) .....	553
Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer. T. TAKAHASHI, N. YAMAMOTO, T. NUKIWA, K. MORI, M. TSUBOI, T. HORAI, N. MASUDA, K. EGUCHI, T. MITSUDOMI, S. YOKOTA, Y. SEGAWA, Y. ICHINOSE, M. FUKUOKA, N. SAIJO ( <i>Shizuoka; Miyagi; Tochigi; Tokyo; Kanagawa; Aichi; Osaka; Ehime; Yamaguchi; Fukuoka, Japan</i> ) .....	557
Repeat Surgery in Patients with Cervical Cancer Stage FIGO IA1: A Series of 156 Cases and A Review of the Literature. L.A. HEFLER, S. POLTERAUER, A. SCHNEITTER, N. CONCIN, G. HOFSTETTER, E. BENTZ, H. LEIPOLD, C. TEMPFER, A. REINTHALLER ( <i>Vienna; Innsbruck; Klagenfurt, Austria</i> ) .....	565
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Cytogenetic Study of 33 Patients Diagnosed Between 1981 and 2008. E. DE BRAEKELEER, N. DOUET-GUILBERT, F. MOREL, M.-J. LE BRIS, A. BASINKO, C. BERTHOU, P. MORICE, C. FÉREC, M. DE BRAEKELEER ( <i>Brest; St-Brieuc, France</i> ) .....	569
Complete Remission of Lung Metastasis Following Adoptive Immunotherapy Using Activated Autologous $\gamma\delta$ T-cells in a Patient with Renal Cell Carcinoma. H. KOBAYASHI, Y. TANAKA, H. SHIMMURA, N. MINATO, K. TANABE ( <i>Tokyo-to; Kyoto; Fukushima, Japan</i> ) .....	575
Successful Neoadjuvant Therapy with Trastuzumab, Paclitaxel and Epirubicin for an Elderly Patient with Inflammatory Breast Cancer. T. SHIMIZU, A. HIRANO, O. WATANABE, J. KINOSHITA, K. KIMURA, M. KAMIMURA, K. DOMOTO, N. KIM, K. OGAWA, M. FUJIBAYASHI ( <i>Tokyo, Japan</i> ) .....	581
Comparison of Circulating MMP-9, TIMP-1 and CA19-9 in the Detection of Pancreatic Cancer. M.T. JOERGENSEN, N. BRÜNNER, O.B.S. DE MUCKADELL ( <i>Odense; Frederiksberg, Denmark</i> ) .....	587
Significant Expression Patterns of Lewis X-related Antigens as a Prognostic Predictor of Low-stage Renal Cell Carcinomas. M. KOBAYASHI, T. MORITA ( <i>Tochigi, Japan</i> ) .....	593
* Review: Reducing Anastomotic Leakage in Oncologic Colorectal Surgery: An Evidence-Based Review. M.A. BOCCOLA, J. LIN, W.M. ROZEN, Y.-H. HO ( <i>Townsville, QLD, Australia</i> ) .....	601
Bevacizumab Is Active as a Single Agent Against Recurrent Malignant Gliomas. C.A. AGHA, S. IBRAHIM, A. HASSAN, D.A. ELIAS, H.M. FATHALLAH-SHAYKH ( <i>Birmingham, AL; Chicago, IL, USA</i> ).....	609
Dendritic Cell Differentiation and Tumor Cell Apoptosis Induced by Components of a Poly-phenylpropanoid Polysaccharide Complex. W.-W. AN, Y. KANAZAWA, M. OZAWA, K. NAKAYA, T. SAITO, A. TANAKA, W.G. BRADLEY ( <i>Niigata; Yokohama, Japan; St. Petersburg, FL, USA</i> ) .....	613

Anthraquinones Danthron and Quinizarin Exert Antiproliferative and Antimetastatic Activity on Murine B16-F10 Melanoma Cells. S. ROSSI, C. TABOLACCI, A. LENTINI, B. PROVENZANO, F. CARLOMOSTI, S. FREZZOTTI, S. BENINATI ( <i>Rome, Italy</i> ) .....	445
Antitumor-promoting Activity of Lignans: Inhibition of Human Cytomegalovirus IE Gene Expression. R. PUSZTAI, M. ABRANTES, J. SHERLY, N. DUARTE, J. MOLNAR, M.-J. U. FERREIRA ( <i>Szeged, Hungary; Lisbon, Portugal</i> ) .....	451
* Review: Epithelial–Stromal Interaction in Squamous Cell Epithelium-derived Tumors: An Important New Player in the Control of Tumor Biological Properties. J. PLZÁK, L. LACINA, M. CHOVANEC, B. DVOŘÁNKOVÁ, P. SZABO, Z. ČADA, K. SMETANA Jr. ( <i>Prague, Czech Republic</i> ) .....	455
Ultrasound-enhanced Microfluidic Synthesis of Liposomes. X. HUANG, R. CADDELL, B. YU, S. XU, B. THEOBALD, L.J. LEE, R.J. LEE ( <i>Columbus, OH, USA</i> ) .....	463
Histological Detection of Minimal Metastatic Disease in Inguinal Non-sentinel Lymph Nodes in Penile Cancer. C.M. NAUMANN, A. MACQUARRIE, C. VAN DER HORST, M.F. HAMANN, A. AL-NAJAR, S. KAUFMANN, A. HEGELE, J.B. KORDA, C. BOLENZ, A. JOCHENS, K.-P. JÜNEMANN, I. LEUSCHNER ( <i>Kiel; Marburg; Cologne; Mannheim, Germany</i> ) .....	467
Erlotinib Enhances the Proapoptotic Activity of Cytotoxic Agents and Synergizes with Paclitaxel in Poorly-differentiated Thyroid Carcinoma Cells. M. LANDRISCINA, F. MADDALENA, A. FABIANO, A. PISCAZZI, O. LA MACCHIA, M. CIGNARELLI ( <i>Foggia, Italy</i> ) .....	473
CADPE Suppresses Cyclin D1 Expression in Hepatocellular Carcinoma by Blocking IL-6-induced STAT3 Activation. C. WON, C.S. LEE, J.-K. LEE, T.-J. KIM, K.-H. LEE, Y.M. YANG, Y.-N. KIM, S.-K. YE, M.-H. CHUNG ( <i>Seoul; Wonju; Chungju; Goyang, South Korea</i> ) .....	481
2'-Hydroxycinnamaldehyde Shows Antitumor Activity against Oral Cancer <i>In Vitro</i> and <i>In Vivo</i> in a Rat Tumor Model. S.-A KIM, Y.-K. SUNG, B.-M. KWON, J.-H. YOON, H. LEE, S.-G. AHN, S.-H. HONG ( <i>Gyeongju; Daegu; Taejeon; Gwangju, South Korea</i> ) .....	489
Effects of $\gamma$ -Secretase Inhibitors on the Growth of Leukemia Cells. Y. OKUHASHI, N. NARA, S. TOHDA ( <i>Tokyo, Japan</i> ) .....	495
Curcumin (Diferuloylmethane) Induces Apoptosis and Blocks Migration of Human Medulloblastoma Cells. M. LATHA Y. BANGARU, S. CHEN, J. WOODLIFF, S. KANSRA ( <i>Milwaukee, WI, USA</i> ) .....	499
Interleukin 1 beta ( <i>IL1B</i> ) Gene Polymorphisms Are Not Associated with Gastric Carcinogenesis in Germany. T. WEX, A. LEODOLTER, J. BORNSCHEIN, D. KUESTER, T. KÄHNE, S. KROPF, C. ALBRECHT, M. NAUMANN, A. ROESSNER, P. MALFERTHEINER ( <i>Magdeburg; Remscheid, Germany</i> ) .....	505
<i>TLR4</i> and <i>NOD2/CARD15</i> Genetic Polymorphisms and their Possible Role in Gastric Carcinogenesis. L. RIGOLI, C. DI BELLA, F. FEDELE, V. PROCOPIO, M. AMORINI, G. LO GIUDICE, P. ROMEO, F. PUGLIATTI, G. FINOCCHIARO, R. LUCIANÒ, R.A. CARUSO ( <i>Messina, Italy</i> ) .....	513
Cytotoxic Effects of <i>N</i> -(3-Chloro-1,4-dioxo 1,4-dihydro-naphthalen-2-yl)-benzamide on Androgen-dependent and -independent Prostate Cancer Cell Lines. Y.M. KANAAN, D.F. WHITE, J.R. DAS, S. BERHE, O. BAKARE, H. KENGUELE, D. BEYENE, Y. ZHOU, A.A. DAY, R.L. COPELAND Jr. ( <i>Washington, DC, USA</i> ) .....	519
Significant Association of <i>XRCC4</i> Single Nucleotide Polymorphisms with Childhood Leukemia in Taiwan. K.-H. WU, C.-H. WANG, Y.-L. YANG, C.-T. PENG, W.-D. LIN, F.-J. TSAI, D.-T. LIN, D.-T. BAU ( <i>Taichung; Taipei, Taiwan, ROC</i> ) .....	529

Inhibitory Effects of Cationic Hybrid Liposomes on the Growth of Human Renal Cell Carcinoma. M. UMEBAYASHI, T. MAKIZONO, H. ICHIHARA, Y. MATSUMOTO, R. UEOKA ( <i>Kumamoto, Japan</i> ) .....	327
Sulindac Sulfone Induces a Decrease of $\beta$ -Catenin in HNSCC. A. SAUTER, H. SOULSBY, K. HORMANN, R. NAIM ( <i>Mannheim, Germany; Coventry, UK; Wiesbaden, Germany</i> ).....	339
Effects of Interleukin-1 Receptor Antagonist and Chemotherapy on Host–Tumor Interactions in Established Melanoma. P.L. TRIOZZI, W. ALDRICH ( <i>Cleveland, OH, USA</i> ) .....	345
Expression and Role of Phosphodiesterase 5 in Human Malignant Melanoma Cell Line. T. MURATA, K. SHIMIZU, Y. WATANABE, H. MORITA, M. SEKIDA, T. TAGAWA ( <i>Tsu, Mie, Japan</i> ) .....	355
Effect of Collagenase and Hyaluronidase on Free and Anomalous Diffusion in Multicellular Spheroids and Xenografts. L. EIKENES, I. TUFTO, E.A. SCHNELL, A. BJØRKØY, C. DE LANGE DAVIES ( <i>Trondheim, Norway</i> ).....	359
Dominant Uptake of Fatty Acid over Glucose by Prostate Cells: A Potential New Diagnostic and Therapeutic Approach. Y. LIU, L.S. ZUCKIER, N.V. GHESANI ( <i>Newark, NJ, USA</i> ).....	369
Tumor-specific Correlation of Tumor M2 Pyruvate Kinase in Pre-Invasive, Invasive and Recurrent Cervical Cancer. S. LANDT, S. JESCHKE, A. KOENINGER, A. THOMAS, T. HEUSNER, S. KORLACH, K. ULM, P. SCHMIDT, J.-U. BLOHMER, W. LICHTENEGGER, J. SEHOULI, S. KUEMMEL ( <i>Essen; Magdeburg; Berlin; Munich, Germany; London, UK</i> ) .....	375
Three-dimensional Cell Culture of Glioma and Morphological Comparison of Four Different Human Cell Lines. Y. MANOME, S. MIZUNO, N. AKIYAMA, K. FUJIOKA, H. SAITO, Y. HATABA, T. KOBAYASHI, M. WATANABE ( <i>Tokyo, Japan; Boston, MA, USA</i> ) .....	383
The <i>In Vitro</i> Effects of Tricyclic Drugs and Dexamethasone on Cellular Respiration of Malignant Glioma. S.C. HIGGINS, G.J. PILKINGTON ( <i>Portsmouth, UK</i> ) .....	391
Prophylactic Noscipine Therapy Inhibits Human Prostate Cancer Progression and Metastasis in a Mouse Model. I. BARKEN, J. GELLER, M. ROGOSNITZKY ( <i>San Diego, CA, USA; Telz Stone, Israel</i> ).....	399
The Combination of 5-FU, Leucovorin and CPT-11 (FOLFIRI) Prolongs Survival through Inhibition of Metastasis in an Orthotopic Model of Colon Cancer. Y. ISHIHARA, K. MATSUNAGA, H. IJIMA, G. HASEGAWA, T. SUZUKI, A.SATO, T. KOBAYASHI, M. YANG, R.M. HOFFMAN ( <i>Fukuoka; Tokyo; Fukushima; Shizuoka, Japan; San Diego, CA, USA</i> ) .....	403
Immune Rejection in a Humanized Model of Murine Prostate Cancer. D. SCHAUER, R.C. KOYA, Y.-P. LIAO, A. RIBAS, W.H. MCBRIDE ( <i>Los Angeles, CA, USA</i> ) .....	409
Pharmacological Impairment of S-Nitrosoglutathione or Thioredoxin Reductases Augments Protein S-Nitrosation in Human Hepatocarcinoma Cells. L.M. LÓPEZ-SÁNCHEZ, F.J. CORRALES, C. LÓPEZ-PEDRERA, E. ARANDA, A. RODRÍGUEZ-ARIZA ( <i>Córdoba; Pamplona, Spain</i> ).....	415
The Influence of Ovarian Cancer Induced Peritoneal Carcinomatosis on the Pharmacokinetics of Albendazole in Nude Mice. M.H. POURGHOLAMI, Z.Y. CAI, S.W.L. CHU, P. GALETTIS, D.L. MORRIS ( <i>Sydney, Australia</i> ) .....	423
Combined $\gamma$ -Tocotrienol and Erlotinib/Gefitinib Treatment Suppresses Stat and Akt Signaling in Murine Mammary Tumor Cells. S.V. BACHAWAL, V.B. WALI, P.W. SYLVESTER ( <i>Monroe, LA, USA</i> ).....	429
(–)-Gossypol Containing Hen Sera and a Myosin (–)-Gossypol Conjugate Reduces the Proliferation of MCF-7 Cells. J.M. REDDISH, W. YE, Y.C. LIN, M. WICK ( <i>Columbus, OH, USA</i> ) .....	439